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Abstract  
Background/Purpose: Coronary heart disease is the leading cause of morbidity in patients 
with type 2 diabetes mellitus (T2DM), frequently resulting in a requirement for coronary 
revascularization using the internal mammary artery (IMA) or saphenous vein (SV). Patency 
rates of SV grafts are inferior to IMA and further impaired by T2DM whilst IMA patencies 
appear similar in both populations. Smooth muscle cells (SMC) play a pivotal role in graft 
integration; we therefore examined the phenotype and proliferative function of IMA- and SV-
SMC isolated from non-diabetic (ND) patients or those diagnosed with T2DM.  
Methods/Materials: SMC were cultured from fragments of SV or IMA. Morphology was 
analyzed under light microscopy (spread cell area measurements) and confocal microscopy 
(F-actin staining). Proliferation was analyzed by cell counting. Levels of RhoA mRNA, protein 
and activity were measured by real-time RT-PCR, western blotting and G-LISA respectively. 
Results: IMA-SMC from T2DM and ND patients were indistinguishable in both morphology 
and function. By comparison, SV-SMC from T2DM patients exhibited significantly larger 
spread cell areas (1.5-fold increase, P<0.05), truncated F-actin fibers and reduced 
proliferation (33% reduction, P<0.05). Furthermore, lower expression and activity of RhoA 
was observed in SV-SMC of T2DM patients (37% reduction in expression, P<0.05 and 43% 
reduction in activity, P<0.01). 
Conclusions: IMA-SMC appear impervious to phenotypic modulation by T2DM. In contrast, 
SV-SMC from T2DM patients exhibit phenotypic and functional changes accompanied by 
reduced RhoA activity. These aberrancies may be epigenetic in nature, compromising SMC 
plasticity and SV graft adaptation in T2DM patients.   
 
Keywords: Type 2 diabetes, smooth muscle cell, saphenous vein, internal mammary artery, 
RhoA; cell phenotype 
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Summary 
The internal mammary artery (IMA) is the conduit of choice for bypass grafting and is 
generally successful in all patients, including those with Type 2 diabetes (T2DM). By 
contrast, saphenous vein (SV) is inferior to IMA and furthermore patients with T2DM suffer 
strikingly poorer outcomes than their non-diabetic (ND) counterparts. We discovered that 
SV-SMC from T2DM patients exhibit altered persistent morphology and function compared 
to ND SV-SMC, with differential expression and activity of the small GTPase RhoA, yet ND 
and T2DM IMA-SMC were indistinguishable. These data offer an explanation for the superior 
patency of IMA grafting independent of the presence of diabetes. 
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Introduction 
Type 2 diabetes mellitus (T2DM) is an escalating global epidemic, and in the UK alone the 
number of patients with diagnosed T2DM has almost doubled over the past 15 years 
(diabetes.org.uk). Importantly, treatment of patients with T2DM and its resultant 
complications now accounts for approximately 10% of the entire UK National Health Service 
budget. One of the leading causes of morbidity and mortality in patients with T2DM is 
accelerated atherosclerosis and coronary heart disease (1) that often precedes clinical 
diagnosis of T2DM (2). 
The surgical approach to revascularizing atherosclerotic coronary arteries is coronary artery 
bypass grafting (CABG) using autologous internal mammary artery (IMA) or saphenous vein 
(SV) to restore blood supply to the ischemic heart. Whilst the IMA is known to be a superior 
conduit with patency rates significantly higher than SV (3), due to its limited availability and 
the need for multiple grafts the SV is routinely the conduit of choice in many patients. 
Furthermore, patients with T2DM have poorer SV graft outcomes compared to their non-
diabetic counterparts (4). Interestingly, this is not the case with IMA, in which patency rates 
are comparable between patients with or without T2DM (reviewed recently in (5)). 
IMA and SV are structurally distinct vessels (3) that respond differently to alterations in 
pressure and cyclical stretching that are evident when vessels are implanted following 
CABG. This leads to changes in vessel structure and function, e.g. altered distensibility and 
stiffness (reviewed in (6)) and intimal abnormalities (7), due at least in part to the orientation 
and behaviour of smooth muscle cells (SMC). Successful integration of grafts early after 
implantation requires efficient adaptive remodeling (8), a process that involves phenotypic 
switching of SMC in terms of co-ordinated migration, proliferation and cytoskeletal 
rearrangement. This functional capacity to adapt is temporally distinct from the subsequent 
neointimal thickening that underlies narrowing and restenosis. The signaling cascades 
regulating these processes are complex and include mitogen activated protein kinases 
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(MAPK) such as extracellular signal related kinase (ERK) and p38 MAPK (9), amongst 
others. Small GTPases and in particular RhoA / Rho kinase are also well recognized 
effectors of such adaptive changes (10). 
RhoA is an archetypal member of the Rho family of small GTPases, activation of which 
promotes formation of F-actin stress fibers and focal adhesions which link stress fibers to the 
plasma membrane, thereby affecting SMC contractility and adhesion (11). RhoA regulates 
many cellular functions including migration and proliferation (11), dysregulation of which are 
implicated in cardiovascular disorders such as hypertension, coronary artery vasospasm and 
neointimal hyperplasia (reviewed in (10)). RhoA is reportedly activated by hyperglycemia, 
and accordingly aberrant RhoA activity has been demonstrated in rodent models of diabetic 
nephropathy (12) and myocardial fibrosis (13). 
We have previously reported inherent differences in the morphology and function of SV-SMC 
from non-diabetic (ND) and T2DM patients; specifically that SV-SMC from patients with 
diabetes exhibited rhomboid-like morphology, altered cytoskeletal arrangement and impaired 
proliferative capacity compared to those isolated from patients without diabetes (14). Of 
particular interest was our observation that the cellular disparities were maintained 
throughout culture and serial passaging and not influenced by glucose concentration. We 
therefore speculated that through prior exposure to the metabolic milieu, SMC from diabetic 
patients show evidence of ³PHPRU\´The aim of this study was therefore to investigate any 
influence of T2DM on IMA-SMC phenotype and to determine a potential role for RhoA.  
 
Materials and Methods 
SMC isolation and culture 
SMC were obtained from IMA and SV fragments from a total 63 different patients undergoing 
CABG at Leeds General Infirmary, UK, and were cultured by explant technique as described 
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previously (15). Local ethical committee approval and informed patient consent was 
obtained. This study conformed to the principles outlined in the Declaration of Helsinki. Cells 
ZHUH PDLQWDLQHG LQ 'XOEHFFR¶V 0RGLILHG (DJOH 0HGLXP '0(0 VXSSOHPHQWHG ZLWK 
fetal calf serum (FCS), 1% L-Glutamine and 1% penicillin / streptomycin / fungizone (full 
growth media ± FGM) at 37oC in 5% CO2 in air. SMC were serially passaged using 
trypsin/EDTA as necessary. All cells were isolated and sub-cultured for up to 6 passages; 
individual experiments were performed on SMC of equivalent passage from age-matched 
donors with diagnosed T2DM or without (ND), characteristics of whom are documented in 
Table 1. All investigations were performed on cells between passages 2-6, an interval over 
which we have previously identified a stable phenotype (14).  
Cell area measurements 
SMC were seeded at a density of 2x105 cells per 75 cm2 flask, cultured for 96 h and then 
examined under phase contrast microscopy at x100 magnification. Fifteen random fields of 
view were captured and the spread areas of 50 cells per patient were measured using 
ImageJ software (http://imagej.nih.gov/ij/). In addition to calculating the average cellular area 
per patient population, data was used to record the distribution of cell sizes (5000 µm2 
increments) within each population. 
Immunocytochemistry 
SMC were seeded at a density of 2x103 per well in Lab-Tek chamberslides, cultured for 96 h 
in FGM and then fixed in 4% paraformaldehyde. Immunostaining for smooth muscle myosin 
heavy chain (SM-MHC; AbCam 1:100), alpha smooth muscle actin (Į-SMA; Sigma-Aldrich 
1:200), F-actin (Invitrogen, 1:50) and vinculin (Sigma-Aldrich, 1:400) was performed 
essentially as previously described (14). Images were visualized using a Zeiss LSM 510 
confocal microscope at x400 magnification. 
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Proliferation assays 
Proliferation assays were performed essentially as we described previously (14). Briefly, 
cells were seeded at 1x104 cells per ml in 24-well plates, cultured for 24 h, then quiesced in 
serum-IUHHPHGLXPIRUKSULRUWRPDNLQJWULSOLFDWHµGD\¶FRXQWVXVLQJtrypan blue and a 
hemocytometer. SMC were maintained in FGM for up to 7 d. Media was replenished on days 
2 and 4 and triplicate viable cell counts taken on days 2, 4 and 7 to generate a growth curve 
from which area under curve (AUC) analysis was performed. 
RhoA real-time RT-PCR 
SMC were seeded at a density of 2x105 in 25 cm2 flasks and cultured in FGM for 96 h before 
total mRNA was isolated as previously described (16). Real-time reverse transcription PCR 
was used to determine RhoA mRNA expression using specific TaqMan assays (Life 
Technologies, Hs00357608_m1). RhoA expression was calculated as a percentage of 
GAPDH (Hs99999905_m1) using the formula 2-ǻ&7 x 100. 
RhoA Western blotting 
Reduced whole cell lysates were prepared and immunoblotted for RhoA (Santa Cruz, 1:100) 
or GAPDH (Sigma-Aldrich, 1:4000) as previously described (17). Expression of RhoA and 
GAPDH was normalized to a single sample that was included on all membranes to allow 
comparison between experiments. 
RhoA activity assay 
SMC were seeded in FGM at a density of 2x105 cells in 25 cm2 tissue culture flasks and 
cultured for 96 h before preparing non-reduced whole cell lysates. RhoA activity was 
measured using a commercial RhoA G-LISATM DFFRUGLQJ WR PDQXIDFWXUHU¶V LQVWUXFWLRQV
(Cytoskeleton, Inc).  
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Statistical analyses 
All results are expressed as mean ± SEM with n representing the number of experiments on 
cells from different patients. Differences between treatment groups were analyzed using 
unpaired ratio t-tests or ratio two-way ANOVA with Bonferroni post-hoc test as appropriate 
(GraphPad Prism software). P<0.05 was considered statistically significant. 
 
Results 
Morphology of IMA and SV-SMC from ND and T2DM patients 
Differences between IMA and SV-SMC were evident soon after explant (typically between 3-
8 days). IMA-SMC presented a wide distribution of spread cell area but ND and T2DM IMA-
SMC were not significantly different (9586 ± 814 µm2 versus 11969 ± 2728 µm2, 
respectively) (Fig. 1A,B).  
In ND patients, venous cells were ~33% smaller in area than arterial cells (6454 ± 947 µm2 
versus 9586 ± 814 µm2). However, when comparing SV-SMC between ND and T2DM 
patients, the latter were significantly larger (1.5-fold increase, 9838 ± 814 µm2, Fig. 1C,D) 
consistent  with our previous report (14). Moreover this phenotype was maintained 
throughout all passages studied (Fig. 1E,F). 
Cytoskeletal morphology of IMA and SV-SMC from ND and T2DM patients 
All cells co-expressed SM-0+&DQGĮ-SMA, confirming their identity as SMC (Fig. 2A,B). In 
IMA-SMC, SM-MHC formed distinct fibers within the cytoplasm and at the cell periphery in 
cells from both ND and T2DM patients (Fig. 2A). In contrast, localization was diffuse 
throughout the cytoplasm of SV-SMC (Fig. 2B) irrespective of diabetic status. This 
suggested that SM-MHC distribution and localization was related to the source of SMC 
rather than being associated with diabetic status. 
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All cells VWDLQHGSRVLWLYHO\ IRUĮ-SMA and although arrangement into fibers was infrequent, 
when present they were visible only in ND SV-SMC (Fig. 2A,B). F-actin formed thin fibers in 
IMA-SMC in both ND and T2DM patients (Fig. 2A). In contrast, SV-SMC from ND patients 
exhibited long stress fibers traversing the cell (Fig. 2B), but this pattern was absent in T2DM 
SV-SMC in which fibers were visibly truncated and disorganized (Fig. 2B).  
Vinculin-positive focal adhesions were sparse in all cell populations, and there were no 
apparent differences between IMA- and SV-SMC from ND or T2DM patients (Fig. 2A,B).  
Proliferative capacity of IMA and SV-SMC from ND and T2DM patients 
In agreement with our previous work (18), ND IMA-SMC exhibited a 50% lower proliferation 
rate than ND SV-SMC (AUC 104.8 ± 22.8 vs. 209.8 ± 18.6 respectively). Importantly, IMA-
SMC proliferation did not differ between the patient cohorts (Fig. 3A,B), unlike SV-SMC 
where it was significantly lower in T2DM patients (32% reduction, Fig. 3C,D), concurrent with 
our previous report (14).  
Cellular RhoA expression  
The small GTPase RhoA is a known regulator of the F-actin cytoskeleton, focal adhesion 
formation and cell proliferation (10;11); we therefore quantified expression (mRNA and 
protein) and activity (GTP-bound) of RhoA in IMA-SMC and SV-SMC. RhoA mRNA and 
protein expression were comparable in IMA-SMC from both ND and T2DM patients and 
RhoA activity, whilst variable between patients, was similar regardless of diabetic status. 
(Fig. 4A-C). In contrast, whilst RhoA mRNA levels were comparable between patient groups 
in SV-SMC (Fig. 4D), protein expression and basal activity of RhoA was significantly lower 
(>40%) in SV-SMC from T2DM compared with ND patients (Fig. 4E,F).  
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Discussion 
In this study we demonstrated that IMA-SMC from T2DM patients were morphologically 
indistinguishable from those of ND patients. In contrast, SV-SMC from T2DM patients 
displayed a distinct phenotype (aberrant morphology, cytoskeletal disarray and impaired 
proliferative capacity) that was accompanied by reduced levels of RhoA expression/activity. 
Effective adaptation to arterial environments early after implantation is a key determinant of 
the long-term patency of SV grafts (8). The ability of vascular SMC to retain plasticity and 
respond (for example through increased cellular proliferation) during adaptation and 
³DUWHULDOL]DWLRQ´ RI WKHJUDIWHG YHLQ LV WKHUHIRUHRIPDMRU LPSRUWDQFH IRU WKH VXFFHVVRI WKH
graft. The distinct T2DM SMC phenotype that we identified appears specific to the SV and 
likely compromises the capacity to remodel and arterialize the venous graft. Crucially, this 
adaptive phase is temporally distinct from subsequent maladaptive intimal thickening and 
occlusion (19). Whilst IMA grafts are superior to SV, importantly they are equally effective in 
patients with and without T2DM, whereas SV grafts in diabetic patients are additionally 
compromised (4;5). The phenotypic differences accompanied by altered RhoA activity 
highlighted in our study may reveal a molecular basis for this clinical phenomenon. 
Cytoskeleton 
We previously described a distinct SV-SMC phenotype from patients with T2DM (14) and in 
the present study, we quantified spread cell areas from IMA and SV sources. IMA-SMC were 
large and more spread than SV-SMC but they did not differ between ND and T2DM patients. 
ND SV-SMC were typically smaller than ND IMA-SMC, and additionally SV-SMC from T2DM 
patients whilst more heterogeneous, were significantly larger than their ND counterparts. 
Because IMA are more successful grafts overall, our data suggest that cell size per se does 
not impair the ability of SMC to form an efficient arterial conduit, but that molecular regulation 
of cytoskeletal structure may be essential.    
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In line with similar spread cell area profiles, the cytoskeleton of IMA-SMC was similar in both 
ND and T2DM patients although all IMA-SMC consistently exhibited a fiber-like arrangement 
of SM-MHC rather than a diffuse staining as observed in SV-SMC. This pattern of staining 
has previously been demonstrated in rabbit aortic SMC where it was associated with cells of 
a contractile phenotype (20), suggesting that under routine culture conditions, IMA-SMC 
exhibit a more contractile phenotype compared to SV-SMC; a phenomenon that is unrelated 
to diabetic status. We previously demonstrated that SV-SMC from patients with T2DM 
H[KLELWHGGLIIXVHĮ-SMA immunoreactivity, truncated F-actin fibers and increased frequency 
of large vinculin-positive focal adhesions compared to those from non-diabetic patients (14). 
The perceived resistance of IMA-SMC to cytoskeletal modulation by T2DM as seen in SV-
SMC may confer functional properties that explain the superior efficacy of IMA grafts. 
Proliferation 
Consistent with our previous findings (18), IMA-SMC proliferated more slowly than SV-SMC 
and here we additionally demonstrate this was not influenced by diabetic status. It appears 
that IMA-SMC may be generally less susceptible to growth factor stimulation than SV-SMC. 
For example, altered PDGF receptor subtype expression (21) and reduced phosphorylation 
levels of ERK in IMA-SMC (18) are possible explanations. Interestingly, inhibition of RhoA 
has been demonstrated to decrease proliferation in SMC (22), supporting a hypothesis that 
impaired cellular RhoA activity as we observed in T2DM-SV-SMC may underlie their 
reduced proliferation capacity with a potentially deleterious effect on graft remodeling.  
RhoA expression and activity 
Rho family GTPases contribute to vascular disorders through modulating vascular cell 
behaviour at least in part via altered F-actin dynamics and proliferation (10;11). Truncated F-
actin fibers and impaired proliferation that we observed in T2DM SV-SMC led us to 
hypothesize that differential RhoA activity may be evident between SV and IMA-SMC, and 
additionally may vary according to diabetic status. Indeed, a previous study reported that the 
12 
 
Rho kinase inhibitor, fasudil, induced greater relaxation responses in intact SV from T2DM 
patients compared to SV from non-diabetic patients. Importantly, this differential sensitivity 
was not evident in IMA from the same patients (23).  
Basal RhoA activity in ND SV- and IMA-SMC were similar. Previous reports comparing 
RhoA mRNA expression between IMA-SMC and SV-SMC have yielded conflicting results, 
reporting either increased (24), or no change in SV expression (21). Our data supports the 
latter, but importantly the G-LISA approach permitted quantification, specifically of RhoA 
activity. 
Published reports relating to the influence of T2DM on RhoA activity and / or expression are 
also at variance. Whilst RhoA is generally upregulated in animal (12;13) and human (23) 
models of diabetes, there are also reports of no differences (25) or marked reductions (26). 
These inconsistencies may arise from both variation in experimental technique and divergent 
expression of RhoA in target tissues. In the current study, expression and activity of RhoA in 
IMA-SMC was similar between the two patient groups. In direct contrast, SV-SMC from 
T2DM patients displayed significantly lower RhoA activity than ND cells. Interestingly, RhoA 
mRNA levels did not vary, suggesting that a mechanism of regulation involving altered 
mRNA stability and/or translational inhibition may exist in vascular SMC. MicroRNAs (miRs) 
are small, non-coding RNAs that negatively regulate target genes in a species- and cell-
specific manner (27). Of particular note, miR-133a is known to target RhoA (28) and is 
reportedly increased in skeletal muscle of a murine model of Type 1 diabetes (29). It is 
therefore possible that differential expression of miRs in T2DM SV-SMC may impact RhoA 
and is an area worthy of further investigation.  
Involvement of SMC phenotypic switching 
Phenotypic switching of SMC from contractile to synthetic states is an area of intense 
research and has been extensively reviewed (30). Increased spread cell area and reduced 
proliferation in SV-SMC from T2DM individuals suggests that the SMC have acquired a more 
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contractile state yet the defective stress fibers and impaired RhoA activation also 
demonstrated are not features of the contractile phenotype. This almost certainly supports 
the concept of complex mechanisms that underlie these changes, some of which may 
include transcription factors, RhoA guanine exchange factors or cell cycle regulators that are 
not associated with differentiation status per se but more related to the acquisition of a 
distinct µGLDEHWes¶ SMC phenotype. Indeed, we have recently reviewed the evidence for 
existence of such a phenotype from diabetes models (31). 
Clinical relevance 
Whilst initially symptomless, the long-term risks to T2DM patients are those of debilitating 
cardiovascular complications. In the clinical setting, the United Kingdom Prospective 
Diabetes Study (UKPDS) reported the advantage of early diagnosis of diabetes and prompt 
glycaemic control leading to a sustained reduction in cardiovascular events (32). Conversely, 
other large clinical trials reported minimal impact of glycaemic control on cardiovascular 
benefit in patients with diabetes and existing clinical CAD (33;34). Such phenomena have 
EHHQ WHUPHG ³PHWDEROLFPHPRU\´ (35). The importance of our data is underscored by the 
observation that the T2DM SV-SMC phenotype cannot be rescued and persists throughout 
culture. We propose that SV-60& ³UHPHPEHU´ SUHYLRXV PHWDEROLF disturbance and 
hyperglycaemia, and display a particular signature that is maintained even after removal of a 
damaging stimulus. The molecular mechanisms underlying this are undoubtedly complex 
although there is emerging evidence for epigenetic mechanisms (36), a fuller understanding 
of which would be potentially valuable.  
Conclusions 
It is unequivocal that in vivo, the structural and mechanical differences between the SV and 
IMA, together with significant endothelial dysfunction impact vascular function. The novelty 
of this study is the observation of a distinct SV-SMC phenotype in T2DM whereas IMA-SMC 
do not appear vulnerable to T2DM-induced phenotypic alterations (cell morphology, 
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cytoskeleton and proliferation). In contrast, SV-SMC isolated from patients with T2DM exhibit 
distinct aberrancies accompanied by reduced levels of RhoA expression and activity. Our 
data may help to explain why IMA grafts are equally robust in both ND and T2DM patients. 
Exploration of epigenetic mechanisms of RhoA expression and activity is an avenue 
potentially amenable to therapeutic manipulation. 
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Figure legends 
Figure 1: SMC morphology. Cells were imaged (x100 magnification) and spread cell areas 
measured using ImageJ. (A) Distribution of cell areas in IMA-SMC with representative phase 
contrast images of ND and T2DM cells (2 each), and (B) mean cell area. (C) Distribution of 
cell areas in SV-SMC with representative phase contrast images of ND and T2DM cells (2 
each), and (D) mean cell area (all n=10 ND and 10 T2DM, *p<0.05, ns = non-significant vs. 
ND, scale bar = 100 µm). The enlarged phenotype observed in T2DM SV-SMC was 
maintained throughout passaging (P2-P6). (E) Representative images (scale bar = ȝm) 
and (F) mean cell area from cells at each passage (n=4 ND and 4 T2DM). Two-way ANOVA 
p = non-significant for the effect of passaging, *p<0.05 for effect of T2DM. 
Figure 2: SMC cytoskeletal morphology. Cells were stained for SM-MHC, Į-SMA, F-actin 
and vinculin, and imaged at x400 magnification. (A) Representative images of cytoskeletal 
morphology in ND and T2DM IMA-SMC and (B) ND and T2DM SV-SMC. Images acquired 
from quadruplicate fields of a minimum of 4 patients for both SV and IMA. Scale bar = 50 
µm.  
Figure 3: SMC proliferation. Growth curves were constructed from viable cell counts made 
over a 7-day period. (A) Proliferation time course of IMA-SMC from ND and T2DM patients; 
(B) area under curve analysis. (C) Proliferation time course of SV-SMC from ND and T2DM 
patients and (D) area under curve analysis. All n=10 ND and 10 T2DM, *p<0.05, ns = non-
significant vs. ND.  
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Figure 4: RhoA mRNA, protein and activity in ND and T2DM SMC. (A) RhoA mRNA 
expression (RT-PCR), (B) protein (immunoblotting) and (C) activity (G-LISA) in ND and 
T2DM IMA-SMC. Comparative analysis performed on SV-SMC for (D) RhoA mRNA, (E) 
protein and (F) activity. In western blots, RhoA protein levels were normalized to GAPDH 
levels from the corresponding sample.  All n=10 ND and 10 T2DM, **p<0.01, *p<0.05, ns = 
non-significant vs. ND. 
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Tables 
  Mean Age (Range) Sex T2DM Treatment 
IMA-SMC  ND n = 19 64.5 years (49-82) 89% Male N/A 
IMA-SMC  T2DM n = 16 61.8 years (34-82) 94% Male 12.4% diet controlled 
43.8% oral therapy 
43.8% oral plus insulin therapy 
SV-SMC    ND n = 25 64.8 years (49-82) 92% Male N/A 
SV-SMC    T2DM n = 23 61.4 years (34-85 100% Male 4.3% diet-controlled 
43.5% oral therapy 
52.2% oral plus insulin therapy 
 
Table 1: Donor patient characteristics. All SMC groups were from age-matched donor patients, predominantly (>90%) male. The 
majority of T2DM patients were receiving oral or oral plus insulin therapies and a smaller percentage were on diet management 
programmes.  
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